Canagliflozin reduced kidney failure and CV events at 2.6 years in type 2 diabetes with chronic kidney disease
Ann Intern Med
.
2019 Aug 20;171(4):JC15.
doi: 10.7326/ACPJ201908200-015.
Author
Tejas Patel
PMID:
31426058
DOI:
10.7326/ACPJ201908200-015
No abstract available
Publication types
Comment
MeSH terms
Canagliflozin
Diabetes Mellitus, Type 2*
Humans
Kidney
Renal Insufficiency, Chronic*
Sodium-Glucose Transporter 2 Inhibitors*
Substances
Sodium-Glucose Transporter 2 Inhibitors
Canagliflozin